The CITE-seq analysis combines single-cell RNA-seq with simultaneous staining for a panel of >40 antibodies conjugated to uniquely barcoded oligonucleotides (henceforth Antibody derived tags, ADTs) aimed to cover the spectrum of normal hematopoietic stem (CD34+CD38-/low fraction) and lineage progenitors (CD34+ enriched fraction, HSPCs) as well as surface markers reported to enrich for CML stem cells (Herrmann et al., 2014; Järås et al., 2010; Kinstrie et al., 2020; Landberg et al., 2018; Sadovnik et al., 2016; Warfvinge et al., 2017). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.